PO-01-044 Erectile Dysfunction in Oncosexology: Multiple Myeloma, Chronic Lymphocytic Leukemia and Chronic Mieloproliferative Neoplasms

Extract

Objective

Erectile dysfunction (ED) is a sexual disfunction in men, defined as a disability to get an erection enough hard for penetration and to sustain that erection until the the end of intercourse, It is present in most of the cases in last 6 months and make the individual stress and unsatisfaction. Erectile disfunction can be primary (from the beginig of sexual life) or secondary ( become later after normal sexual activity). Aims: The aim of the study is to find prevalence and severity of erectile disfunction in male patients with hematological malignant diseases: chronic lymfocytic leukemia, disseminated multiple myeloma and myeloproliferative neoplasms at diagnosis and after 1 year of treatment.

Methods

Patients were classified into three groups based on diagnosis, the WHO performance status, hemoglobin level, renal function, present or absent another vascular disease ( cerebral stroke, peripheral occlusive disease, coronary disease and diabetes mellitus. Methods: All the patients answered at diagnosis questionary 5 item version of the International index of erectile disfunction IIEF- 5 with specificity 0,88 and sensitivity 0,97. After one year of therapy, survivors answered the same 5 questions, each of them has 0 - 5 point and max 25 points. The score depend on severity of erectile disfunction and classified like severe ED 1- 7points, moderate 8- 11, mild to moderate 12 -16, mild 17 - 21, normal erectile function 22 - 25 points. The study include 60 male patients : 20 with chronic lymphatic leukemia, 20 with multiple myeloma and 20 with myeloproliferative neoplasms.